- LakeShore Biopharma Co., Ltd. has entered into a definitive **Merger Agreement** with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. for a **going-private transaction**.  **[1946399_0001213900-25-105603_ea026359201ex99-1_lakeshore.htm:0]** 
- The transaction implies an equity value of approximately **US$37 million**.  **[1946399_0001213900-25-105603_ea026359201ex99-1_lakeshore.htm:0]** 
- Each ordinary share will be cancelled in exchange for **US$0.90 in cash per Share**.  **[1946399_0001213900-25-105603_ea026359201ex99-1_lakeshore.htm:0]** **[1946399_0001213900-25-105603_ea026359201ex99-2_lakeshore.htm:17]**  This represents a premium of approximately **15.4%** to the closing price on August 15, 2025, and **16.6%** to the average closing price over the last 15 trading days prior to and including August 15, 2025.  **[1946399_0001213900-25-105603_ea026359201ex99-1_lakeshore.htm:0]** 
- The merger is expected to close during the **first quarter of 2026** and will result in the company becoming privately held, with its shares no longer quoted on the OTC Pink Open Market.  **[1946399_0001213900-25-105603_ea026359201ex99-1_lakeshore.htm:1]**  Rollover Shareholders, representing approximately **53.35%** of the voting rights, have agreed to vote in favor of the merger.  **[1946399_0001213900-25-105603_ea026359201ex99-1_lakeshore.htm:1]**

LakeShore Biopharma Enters Definitive Agreement for Going-Private Transaction

- LakeShore Biopharma (LSBCF) has entered into a definitive merger agreement with Oceanpine Skyline Inc. for a going-private transaction, implying an equity value of approximately **US$37 million** for the company.  **[1946399_20251104CN15011:0]** 
- Under the terms, each ordinary share will be cancelled in exchange for **US$0.90 in cash**, representing a **15.4% premium** to the closing price on August 15, 2025.  **[1946399_20251104CN15011:0]** 
- The merger is expected to close during the **first quarter of 2026** and will result in LakeShore Biopharma becoming a privately held company, with its shares no longer quoted on the OTC Pink Open Market.  **[1946399_20251104CN15011:1]** 
- Rollover Shareholders, holding approximately **53.35%** of the voting rights, have agreed to vote in favor of the merger.  **[1946399_20251104CN15011:1]**